Canlyniadau Chwilio - C. Logothetis

  • Dangos 1 - 4 canlyniadau o 4
Mireinio'r Canlyniadau
  1. 1
    Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases

    Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases gan Hisanori Uehara, Seung Jun Kim, Takashi Karashima, David L. Shepherd, D. Fan, R. Tsan, Jerald J. Killion, C. Logothetis, Paul Mathew, Isaiah J. Fidler

    Cyhoeddwyd 2003
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

    A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma gan Amado J. Zurita, Eric Jonasch, X Wang, Mehrdad Khajavi, Shaoyu Yan, D. Z. Du, Li Xu, Matthew H. Herynk, Kimberly S. McKee, Hai T. Tran, C. Logothetis, Nizar M. Tannir, John V. Heymach

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties

    Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties gan Anurag N. Paranjape, Rama Soundararajan, Steven J. Werden, Robiya Joseph, Joseph H. Taube, Hui Liu, Jaime Rodriguez‐Canales, Nathalie Sphyris, Ignacio I. Wistuba, Naoyuki Miura, Jasreman Dhillon, Nupam P. Mahajan, Kiran Mahajan, John T. Chang, Michael Ittmann, Sankar N. Maity, C. Logothetis, Dean G. Tang, Sendurai A. Mani

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multic... gan Eugene D. Kwon, Charles G. Drake, H. I. Scher, Karim Fizazi, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor‐Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, C. Logothetis, Tomasz M. Beer, M. Brent McHenry, Paul Gagnier, David Liu, Winald R. Gerritsen

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: